Do we always need to treat patients with spinal muscular atrophy? A personal view and experience

BACKGROUND: We report the clinical outcomes observed in our patients with SMA type 1 or 2 receiving nusinersen, and we comment on the ethical implications of this treatment, in line with our results and those reported by Audic et al. in their analysis published in the Orphanet Journal of Rare Diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Agosto, Caterina, Salamon, Eleonora, Divisic, Antuan, Benedetti, Francesca, Giacomelli, Luca, Shah, Aashni, Perilongo, Giorgio, Benini, Franca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879688/
https://www.ncbi.nlm.nih.gov/pubmed/33573692
http://dx.doi.org/10.1186/s13023-020-01593-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879688/
https://www.ncbi.nlm.nih.gov/pubmed/33573692
http://dx.doi.org/10.1186/s13023-020-01593-4

Ejemplares similares